Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bromodomains are gaining increasing interest as drug targets. Commercially sourced and de novo synthesized substituted [1,2,4]triazolo[4,3-a]phthalazines are potent inhibitors of both the BET bromodomains such as BRD4 as well as bromodomains outside the BET family such as BRD9, CECR2, and CREBBP. This new series of compounds is the first example of submicromolar inhibitors of bromodomains outside the BET subfamily. Representative compounds are active in cells exhibiting potent cellular inhibition activity in a FRAP model of CREBBP and chromatin association. The compounds described are valuable starting points for discovery of selective bromodomain inhibitors and inhibitors with mixed bromodomain pharmacology.

Original publication

DOI

10.1021/jm401568s

Type

Journal article

Journal

J Med Chem

Publication Date

23/01/2014

Volume

57

Pages

462 - 476

Keywords

CREB-Binding Protein, Cell Cycle Proteins, Cell Line, Tumor, Chromatin Assembly and Disassembly, Crystallography, X-Ray, Humans, Molecular Docking Simulation, Nuclear Proteins, Phthalazines, Protein Structure, Tertiary, Proteins, Structure-Activity Relationship, Transcription Factors, Triazoles